125 related articles for article (PubMed ID: 32865865)
1. Increased toxicities in children with Burkitt lymphoma treated with rituximab: Experience from a tertiary cancer center in India.
Srinivasan S; Roy Moulik N; Kc A; Narula G; Sankaran H; Prasad M; Dhamne C; Cheriyalinkal Parambil B; Shah S; Shet T; Sridhar E; Gujral S; Banavali S
Pediatr Blood Cancer; 2020 Nov; 67(11):e28682. PubMed ID: 32865865
[TBL] [Abstract][Full Text] [Related]
2. [Clinical Efficacy and Prognostic Factors of Newly Diagnosed Children[JP] with Burkitt Lymphoma Treated by High-Dose and Short-Course Modified LMB Regimen ± Rituximab].
Wang BT; Dang HB; Wei YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):529-534. PubMed ID: 32319391
[TBL] [Abstract][Full Text] [Related]
3. Rituximab is highly effective in children and adolescents with Burkitt lymphoma in Risk Groups R2 to R4.
Zhen Z; Zhu J; Wang J; Lu S; Sun F; Huang J; Sun X
Pediatr Hematol Oncol; 2020 Sep; 37(6):489-499. PubMed ID: 32364412
[TBL] [Abstract][Full Text] [Related]
4. [Clinical features and prognosis of children with Burkitt's lymphoma: an analysis of 62 cases].
Wang YC; DU WC; Yin CY; Gong X; Li YF
Zhongguo Dang Dai Er Ke Za Zhi; 2022 May; 24(5):561-565. PubMed ID: 35644197
[TBL] [Abstract][Full Text] [Related]
5. Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study.
Rigaud C; Auperin A; Jourdain A; Haouy S; Couec ML; Aladjidi N; Gandemer V; Lambliotte A; Plat G; Landman-Parker J; Michon J; Leblanc T; Patte C; Minard-Colin V
Pediatr Blood Cancer; 2019 Sep; 66(9):e27873. PubMed ID: 31207026
[TBL] [Abstract][Full Text] [Related]
6. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
[TBL] [Abstract][Full Text] [Related]
7. Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy.
Alwan F; He A; Montoto S; Kassam S; Mee M; Burns F; Edwards S; Wilson A; Tenant-Flowers M; Marcus R; Ardeshna KM; Bower M; Cwynarski K
AIDS; 2015 May; 29(8):903-10. PubMed ID: 25730506
[TBL] [Abstract][Full Text] [Related]
8. [Effect of Modified LMB 89± Rituximab Regimen on Long-Term Benefits for Patients's with Burkitt Lymphoma].
Tan L; Xie Y; Yang J; Liu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):872-875. PubMed ID: 32552950
[TBL] [Abstract][Full Text] [Related]
9. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcome in children with central nervous system-positive Burkitt lymphoma using only intrathecal and systemic chemotherapy combined with rituximab.
Huang S; Jin L; Yang J; Duan YL; Zhang M; Zhou CJ; Zhang YH
Chin Med J (Engl); 2021 Mar; 134(11):1329-1334. PubMed ID: 33734131
[TBL] [Abstract][Full Text] [Related]
11. Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.
Mori T; Osumi T; Kada A; Ohki K; Koga Y; Fukano R; Fujita N; Mitsui T; Mori T; Saito AM; Nakazawa A; Kobayashi R; Sekimizu M
Eur J Haematol; 2024 Apr; 112(4):585-593. PubMed ID: 38112205
[TBL] [Abstract][Full Text] [Related]
12. [Mid-term efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma 2017 regimen in the treatment of pediatric Burkitt lymphoma].
Zhang M; Wu P; Duan YL; Jin L; Yang J; Huang S; Liu Y; Hu B; Zhai XW; Wang HS; Fu Y; Li F; Yang XM; Liu AS; Qin S; Yuan XJ; Dong YS; Liu W; Zhou JW; Zhang LP; Jia YP; Wang J; Qu LJ; Dai YP; Guan GT; Sun LR; Jiang J; Liu R; Jin RM; Wang ZJ; Wang XG; Zhang BX; Chen KL; Zhuang SQ; Zhang J; Zhou CJ; Gao ZF; Zheng MC; Zhang Y
Zhonghua Er Ke Za Zhi; 2022 Oct; 60(10):1011-1018. PubMed ID: 36207847
[No Abstract] [Full Text] [Related]
13. Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative.
Afify Z; Orjuela-Grimm M; Smith CM; Dalal M; Ford JB; Pillai P; Robles JM; Reddy S; McCormack S; Ehrhardt MJ; Ureda T; Alperstein W; Edington H; Miller TP; Rubinstein JD; Kavanaugh M; Bukowinski AJ; Friehling E; Rivers JM; Chisholm KM; Marks LJ; Mason CC
Br J Haematol; 2023 Feb; 200(3):297-305. PubMed ID: 36454546
[TBL] [Abstract][Full Text] [Related]
14. The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab.
Forero-Castro M; Robledo C; Lumbreras E; Benito R; Hernández-Sánchez JM; Hernández-Sánchez M; García JL; Corchete-Sánchez LA; Tormo M; Barba P; Menárguez J; Ribera J; Grande C; Escoda L; Olivier C; Carrillo E; García de Coca A; Ribera JM; Hernández-Rivas JM
Br J Haematol; 2016 Feb; 172(3):428-38. PubMed ID: 26567765
[TBL] [Abstract][Full Text] [Related]
15. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.
Fayad L; Thomas D; Romaguera J
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S57-62. PubMed ID: 18284717
[TBL] [Abstract][Full Text] [Related]
16. Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy.
Woessmann W; Zimmermann M; Meinhardt A; Müller S; Hauch H; Knörr F; Oschlies I; Klapper W; Niggli F; Kabickova E; Attarbaschi A; Reiter A; Burkhardt B
Blood; 2020 Apr; 135(14):1124-1132. PubMed ID: 31961927
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of serum immunoglobulin level in children with Burkitt lymphoma].
Zhang M; Ma XL; Duan YL; Jin L; Yang J; Huang S; Li N; Zhang N; Zhang NN; Zhang YH
Zhonghua Er Ke Za Zhi; 2022 Apr; 60(4):329-333. PubMed ID: 35385939
[No Abstract] [Full Text] [Related]
18. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
[TBL] [Abstract][Full Text] [Related]
19. [Clinical and prognostic analysis of 186 children with Burkitt's lymphoma].
Zhang M; Jin L; Yang J; Duan YL; Huang S; Zhou CJ; Zhang YH
Zhonghua Er Ke Za Zhi; 2018 Aug; 56(8):605-610. PubMed ID: 30078243
[No Abstract] [Full Text] [Related]
20. [Clinical analysis of a modified LMB89 Group C regimen in the treatment of pediatric high-risk Burkitt lymphoma].
Zhang M; Jin L; Yang J; Duan YL; Huang S; Zhou CJ; Zhang YH
Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):633-638. PubMed ID: 31495128
[No Abstract] [Full Text] [Related]
[Next] [New Search]
